A Multicenter, Phase IB/II Study of Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abemaciclib (Primary) ; Bicalutamide (Primary)
Indications Advanced breast cancer; Bone metastases; HER2 negative breast cancer
Focus Adverse reactions

20 Feb 2024 Planned End Date changed from 1 Sep 2024 to 1 Oct 2026.
20 Feb 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Apr 2025.
08 Nov 2022 Planned End Date changed from 1 Jan 2024 to 1 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com